Transforming the RNA Therapeutics Industry with a Next-Generation Delivery System | Interview with Nigel Theobald, CEO of N4 Pharma
An interview with Nigel Theobald, CEO of N4 Pharma As featured on the Life Sciences Decoded Podcast
|
|
RNA therapeutics promise to deliver next-generation medicines—but one of the greatest obstacles is delivering them to the right tissues safely and effectively.
On a recent episode of Life Sciences Decoded, we sat down with Nigel Throbald, CEO of N4 Pharma, a company bringing solutions to one of biopharma’s biggest blind spots. N4 Pharma is developing Nuvec®, its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases. Nuvec® has several key advantages for RNA gene delivery including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing, protection of the RNA payload to allow for oral delivery, no unwanted immune response and excellent stability and storage. |
Shorts
|
The Power of RNA Therapy
|
The Challenges of RNA Therapies
|
Real World Example: N4 101
|
Inspired by this story? Tell us yours!
We feature innovators shaping the future of biotech, diagnostics, and healthcare. If that’s you, let’s talk.
|
|
Topics We Cover
|